Amneal Pharmaceuticals Inc (AMRX)

$12.71 -0.64 (-4.79%)
Market Cap 4.20B
Revenue (ttm) 3.02B
Net Income (ttm) 72.06M
EPS (ttm) N/A
PE Ratio 17.43
Forward PE 14.56
Profit Margin 2.39%
Debt to Equity Ratio -36.06
Volume 3,767,500
Avg Vol 2,659,918
Day's Range N/A - N/A
Shares Out 314.36M
Stochastic %K 8%
Beta 1.35
Analysts Strong Sell
Price Target $16.80

Company Profile

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, ste...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 947 3120
Fax: 908 947 3146
Address:
400 Crossing Boulevard, 3rd Floor, Bridgewater, United States
tamperson
tamperson Mar. 11 at 4:14 PM
$AMRX Found it… a hit piece article on generic drug companies. “Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment”.
0 · Reply
tamperson
tamperson Mar. 11 at 4:07 PM
$AMRX what’s the bad news dropping the price this morning?
0 · Reply
erevnon
erevnon Mar. 2 at 3:31 PM
Truist Securities maintains Amneal Pharmaceuticals $AMRX at Buy and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Estimize
Estimize Mar. 2 at 2:03 PM
Wall St is expecting 0.18 EPS for $AMRX Q1 [Reporting 05/01 BMO] http://www.estimize.com/intro/amrx?chart=historical&metric_name=eps&utm_co
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 27 at 11:25 AM
$AMRX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.11 up 210.00% YoY • Reported revenue of $814.32M up 11.47% YoY • Amneal Pharmaceuticals Inc. provides 2026 financial guidance of $3.05 to $3.15B in net revenue, $720 to $760M in Adjusted EBITDA, and $0.93 to $1.03 in Adjusted Diluted EPS.
0 · Reply
StockNews_Live
StockNews_Live Feb. 27 at 11:01 AM
$AMRX Amneal Pharmaceuticals, Inc. announced its results for the fourth quarter and full year ended December 31, 2025. Net revenue in the fourth quarter of 2025 was $814 million, an increase of 11% compared…
0 · Reply
spoppies
spoppies Feb. 26 at 9:12 PM
$AMRX excited for the earnings tomorrow.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 20 at 8:22 PM
$AMRX Share Price: $14.52 Contract Selected: Sep 18, 2026 $15 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.80 – $0.98 Potential Upside: 78% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 1:28 PM
$AMRX RSI: 72.82, MACD: 0.4917 Vol: 0.54, MA20: 14.20, MA50: 13.28 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 1:13 AM
$AMRX Current Stock Price: $15.19 Contracts to trade: $15.0 AMRX Feb 20 2026 Call Entry: $0.15 Exit: $0.25 ROI: 68% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on AMRX
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 10, 2026, 5:40 PM EDT - 1 day ago

Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Amneal to Participate in Upcoming Investor Conference

Mar 5, 2026, 4:05 PM EST - 6 days ago

Amneal to Participate in Upcoming Investor Conference

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript

Feb 27, 2026, 10:17 AM EST - 12 days ago

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript

Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 27, 2026, 6:00 AM EST - 12 days ago

Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

Jan 28, 2026, 4:05 PM EST - 6 weeks ago

Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

Jan 27, 2026, 6:02 PM EST - 6 weeks ago

TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

AEIS AHR APLS BROS CADE CIVI CMA

Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

Jan 27, 2026, 8:00 AM EST - 6 weeks ago

Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 11:36 PM EST - 2 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease

Jan 9, 2026, 11:00 AM EST - 2 months ago

KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson's Disease

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

Dec 22, 2025, 4:01 PM EST - 2 months ago

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks

Dec 17, 2025, 11:01 PM EST - 3 months ago

Amneal: Growing Drug Portfolio, Positive Cash Flow, Outweighing Leverage Risks

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

Dec 9, 2025, 4:01 PM EST - 3 months ago

Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease

Dec 5, 2025, 8:00 AM EST - 3 months ago

Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson's Disease

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

Dec 2, 2025, 8:00 AM EST - 3 months ago

Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

Amneal to Participate in Upcoming Investor Conferences

Dec 2, 2025, 8:00 AM EST - 3 months ago

Amneal to Participate in Upcoming Investor Conferences

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

Dec 1, 2025, 4:01 PM EST - 3 months ago

Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

Amneal Receives U.S. FDA Approval for Iohexol Injection

Nov 13, 2025, 4:01 PM EST - 4 months ago

Amneal Receives U.S. FDA Approval for Iohexol Injection

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 12:56 PM EDT - 4 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2025 Earnings Call Transcript

Amneal Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 AM EDT - 4 months ago

Amneal Reports Third Quarter 2025 Financial Results

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

Oct 29, 2025, 4:05 PM EDT - 4 months ago

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Oct 27, 2025, 8:00 AM EDT - 4 months ago

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Amneal to Report Third Quarter 2025 Results on October 30, 2025

Sep 30, 2025, 4:05 PM EDT - 5 months ago

Amneal to Report Third Quarter 2025 Results on October 30, 2025

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

Sep 26, 2025, 8:00 AM EDT - 5 months ago

Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

Sep 23, 2025, 8:00 AM EDT - 6 months ago

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

Sep 11, 2025, 8:00 AM EDT - 6 months ago

Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution

Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing

Sep 11, 2025, 7:23 AM EDT - 6 months ago

Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

Sep 4, 2025, 4:01 PM EDT - 6 months ago

Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 2:56 PM EDT - 7 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q2 2025 Earnings Call Transcript

Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico

Aug 5, 2025, 7:30 AM EDT - 7 months ago

Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico

Amneal Reports Second Quarter 2025 Financial Results

Aug 5, 2025, 6:00 AM EDT - 7 months ago

Amneal Reports Second Quarter 2025 Financial Results

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

Jul 21, 2025, 7:39 AM EDT - 8 months ago

Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

Jul 21, 2025, 7:38 AM EDT - 8 months ago

Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Jul 18, 2025, 7:00 AM EDT - 8 months ago

Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada

Amneal to Report Second Quarter 2025 Results on August 5, 2025

Jul 9, 2025, 8:00 AM EDT - 8 months ago

Amneal to Report Second Quarter 2025 Results on August 5, 2025

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Jun 25, 2025, 8:00 AM EDT - 9 months ago

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Jun 12, 2025, 8:00 AM EDT - 9 months ago

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

Amneal to Participate at Upcoming Investor Conferences in June

May 29, 2025, 4:05 PM EDT - 10 months ago

Amneal to Participate at Upcoming Investor Conferences in June

US FDA approves Amneal's migraine treatment

May 15, 2025, 8:16 AM EDT - 10 months ago

US FDA approves Amneal's migraine treatment

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

May 15, 2025, 8:00 AM EDT - 10 months ago

Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

May 8, 2025, 7:00 AM EDT - 10 months ago

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript

May 2, 2025, 11:32 AM EDT - 11 months ago

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript

Amneal Reports First Quarter 2025 Financial Results

May 2, 2025, 6:00 AM EDT - 11 months ago

Amneal Reports First Quarter 2025 Financial Results

Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

Apr 11, 2025, 8:00 AM EDT - 11 months ago

Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

Amneal to Report First Quarter 2025 Results on May 2, 2025

Apr 8, 2025, 4:05 PM EDT - 1 year ago

Amneal to Report First Quarter 2025 Results on May 2, 2025

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Mar 19, 2025, 3:14 PM EDT - 1 year ago

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Amneal to Participate at Upcoming Investor Conference

Mar 10, 2025, 4:05 PM EDT - 1 year ago

Amneal to Participate at Upcoming Investor Conference

Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Mar 3, 2025, 4:05 PM EST - 1 year ago

Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

tamperson
tamperson Mar. 11 at 4:14 PM
$AMRX Found it… a hit piece article on generic drug companies. “Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment”.
0 · Reply
tamperson
tamperson Mar. 11 at 4:07 PM
$AMRX what’s the bad news dropping the price this morning?
0 · Reply
erevnon
erevnon Mar. 2 at 3:31 PM
Truist Securities maintains Amneal Pharmaceuticals $AMRX at Buy and raises the price target from $15 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Estimize
Estimize Mar. 2 at 2:03 PM
Wall St is expecting 0.18 EPS for $AMRX Q1 [Reporting 05/01 BMO] http://www.estimize.com/intro/amrx?chart=historical&metric_name=eps&utm_co
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 27 at 11:25 AM
$AMRX Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.11 up 210.00% YoY • Reported revenue of $814.32M up 11.47% YoY • Amneal Pharmaceuticals Inc. provides 2026 financial guidance of $3.05 to $3.15B in net revenue, $720 to $760M in Adjusted EBITDA, and $0.93 to $1.03 in Adjusted Diluted EPS.
0 · Reply
StockNews_Live
StockNews_Live Feb. 27 at 11:01 AM
$AMRX Amneal Pharmaceuticals, Inc. announced its results for the fourth quarter and full year ended December 31, 2025. Net revenue in the fourth quarter of 2025 was $814 million, an increase of 11% compared…
0 · Reply
spoppies
spoppies Feb. 26 at 9:12 PM
$AMRX excited for the earnings tomorrow.
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 20 at 8:22 PM
$AMRX Share Price: $14.52 Contract Selected: Sep 18, 2026 $15 Calls Buy Zone: $0.42 – $0.53 Target Zone: $0.80 – $0.98 Potential Upside: 78% ROI Time to Expiration: 209 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 1:28 PM
$AMRX RSI: 72.82, MACD: 0.4917 Vol: 0.54, MA20: 14.20, MA50: 13.28 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 1:13 AM
$AMRX Current Stock Price: $15.19 Contracts to trade: $15.0 AMRX Feb 20 2026 Call Entry: $0.15 Exit: $0.25 ROI: 68% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
JackAnalyst
JackAnalyst Feb. 17 at 7:09 PM
Healthcare isn’t slowing. It’s shifting. OTC, generics, devices: $AMRX $PBH $VKTX $PODD Early consumer wellness exposure $MOOD.CSE Accessibility is the theme. Watching this space closely.
0 · Reply
soddo40725
soddo40725 Feb. 13 at 1:03 PM
$AMRX wowwwww
0 · Reply
SuperGreenToday
SuperGreenToday Feb. 12 at 1:24 PM
$AMRX Share Price: $14.69 Contract Selected: Sep 18, 2026 $15 Calls Buy Zone: $2.22 – $2.74 Target Zone: $3.92 – $4.79 Potential Upside: 67% ROI Time to Expiration: 217 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WAJeff
WAJeff Jan. 29 at 8:56 PM
$AMRX Got added to SmallCap 600, not a bad chart. Had a bid for this at 13.61 that hasn’t filled
1 · Reply
killer_7
killer_7 Jan. 28 at 4:42 PM
$AMRX adding big here
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 12:00 PM
$AMRX RSI: 66.08, MACD: 0.3040 Vol: 0.30, MA20: 13.09, MA50: 12.51 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
harmongreg
harmongreg Jan. 19 at 9:20 PM
Dragonfly Capital - 5 Trade Ideas for Monday: Amneal Pharma, Amex, Graco, Corning and Walmart $AMRX $AXP $GGG $GLW $WMT https://dragonflycap.com/5-trade-ideas-for-monday-amneal-pharma-amex-graco-corning-and-walmart/
0 · Reply
G101SPM
G101SPM Jan. 13 at 12:59 PM
$AMRX $13.05 Holding long position. EXIT $19.00 https://stocktwits.com/G101SPM/message/583492963 BRIEF: Amneal Pharmaceuticals expects to meet or exceed FY25 guidance . Prior guidance: Co issues in-line guidance for FY25 (Dec), sees EPS of $0.75-0.80 vs. $0.80 consensus.
0 · Reply
vcdc
vcdc Jan. 9 at 4:11 PM
$AMRX KeifeRx, a privately held biotechnology company developing disease-modifying therapies for neurodegenerative disorders, today announced that it has entered into a research collaboration and option agreement with Amneal Pharmaceuticals to support the pre-IND development of KFRX06, KeifeRx’s preclinical candidate designed to inhibit leucine-rich repeat kinase 2 (LRRK2), a gene strongly implicated in Parkinson’s disease biology.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 10:23 PM
$AMRX RSI: 67.58, MACD: 0.3329 Vol: 0.33, MA20: 12.36, MA50: 11.64 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Merlintrader
Merlintrader Dec. 26 at 8:49 PM
$AMRX https://www.merlintrader.com/amrx-amneal/
0 · Reply
ActuaryAlpha
ActuaryAlpha Dec. 25 at 7:57 AM
$AMRX Market tolerance narrows as uncertainty lingers, amid evolving funding conditions and shifting competitive responses. Absent traction, patience will erode.
0 · Reply